Edwards Lifesciences Co. (NYSE:EW) VP Catherine M. Szyman sold 10,000 shares of the business’s stock in a transaction on Friday, January 14th. The shares were sold at an average price of $119.53, for a total transaction of $1,195,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
EW stock traded down $2.20 during trading on Friday, hitting $118.26. The company had a trading volume of 2,112,636 shares, compared to its average volume of 2,161,996. The firm has a market capitalization of $73.83 billion, a price-to-earnings ratio of 51.26, a P/E/G ratio of 3.45 and a beta of 1.10. The business has a 50 day moving average of $119.68 and a 200 day moving average of $115.70. Edwards Lifesciences Co. has a fifty-two week low of $78.44 and a fifty-two week high of $131.73. The company has a current ratio of 3.64, a quick ratio of 2.87 and a debt-to-equity ratio of 0.11.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, October 27th. The medical research company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.01. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. Edwards Lifesciences had a net margin of 29.00% and a return on equity of 28.13%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.51 earnings per share. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.26 EPS for the current year.
Several research firms have weighed in on EW. Royal Bank of Canada began coverage on shares of Edwards Lifesciences in a research note on Thursday, December 9th. They set an “outperform” rating and a $142.00 target price for the company. Citigroup upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $120.00 to $142.00 in a research note on Wednesday, December 15th. SVB Leerink boosted their target price on shares of Edwards Lifesciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Thursday, December 9th. Jefferies Financial Group boosted their target price on shares of Edwards Lifesciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, October 29th. Finally, Piper Sandler boosted their target price on shares of Edwards Lifesciences from $123.00 to $133.00 and gave the company an “overweight” rating in a research note on Wednesday, December 8th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $125.30.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.
Recommended Story: What are retained earnings?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.